Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL.

摘要: Immunization of cancer patients with tumor-specific antigenic peptides is currently being tested in several clinical studies. We have examined the induction CTL responses mice after various modalities peptide vaccination, to explore protocols that could be applied humans. Our first model antigen was P198, which results from a point mutation normal gene. While two immunizations P198 SBAS-1c adjuvant induced measurable less than 10% DBA/2 mice, addition IL-12 mixture resulted high nearly all mice. This strong enhancing effect observed 1,000 and 300 units decreased gradually as doses were reduced 30 units. When replaced by other cytokines acting on T cells or antigen-presenting cells, such IFN-gamma, IL-2, IL-6, IL-7, GM-CSF MCP-3, no significant observed. The same obtained P1A, major mastocytoma P815 encoded gene specifically activated tumors.